Tirzepatide versus usual care for adults with obesity (no diabetes) in UK primary care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 interventional study will enroll adults with obesity but without diabetes and compare treatment with tirzepatide to standard of care over about 260 weeks in a real-world primary care setting. Participants must have BMI 30–34.9 kg/m2, an elevated waist-to-height ratio (>0.5), at least one weight-related comorbidity, and a prior attempt at lifestyle weight loss; people with any form of diabetes or recent large weight change are excluded. The trial will use data from participating UK primary care practices and electronic health records to track body weight changes and new diagnoses of type 2 diabetes. Outcomes aim to reflect effectiveness and safety of tirzepatide when used alongside routine clinical care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2)
* Have an increased waist to height ratio (defined by \>0.5)
* Have at least one weight related comorbid condition
* Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)

Exclusion Criteria:

* Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
* Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening

Where it's running

• P89008 Ashton Medical Group
  Ashton-under-Lyne, United Kingdom Recruiting
• P89002 The Brooke Surgery
  Hyde SK14, United Kingdom Recruiting
• P84035 Bodey Medical Centre
  Manchester, United Kingdom Recruiting
• P84630 The Arch Medical Practice
  Manchester, United Kingdom Recruiting
• P86004 Peterloo Medical Centre
  Manchester, United Kingdom Recruiting
• P87019 Silverdale Medical Practice
  Manchester, United Kingdom Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.